Patent: 7,989,486
✉ Email this page to a colleague
Summary for Patent: 7,989,486
Title: | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions |
Abstract: | The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3\'-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV. |
Inventor(s): | Zeligs; Michael A. (Boulder, CO) |
Assignee: | Bioresponse, L.L.C. (Boulder, CO) |
Application Number: | 11/322,803 |
Patent Claims: | see list of patent claims |
Details for Patent 7,989,486
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2024-12-30 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2024-12-30 |
Hoffmann-la Roche Inc. | PEGASYS COPEGUS COMBINATION PACK | peginterferon alfa-2a and ribavirin | 125083 | 06/04/2004 | ⤷ Try a Trial | 2024-12-30 | |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2024-12-30 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2024-12-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |